The FDA expected to approve Pfizer’s Covid vaccine for teens aged 12-15 in the next WEEK
- The Food and Drug Administration prepares to approve Pfizer’s Covid vaccine for people 12-5 years old, officials told the New York Times
- The authorization is expected to come late this week or early next week
- The Pfizer vaccine was approved in the US in December for anyone 16 or older
- A trial conducted from October to March found that the injection of Pfizer was 100% effective in preventing serious illness or death in 12-15 year olds
- However, less than 0.1 percent of all U.S. Covid fatalities were in children under the age of 18, raising questions about whether children will get shots just to protect adults
US regulators expect Pfizer’s Covid vaccine to be given a green light to teens between the ages of 12 and 15 as early as the end of this week. the New York Times.
The shot was approved in December for people 16 and older, and Pfizer has been in trials for teens since October last year.
Expanding the study to younger teens will make about 13 million additional Americans eligible for vaccination, a step that some consider critical to achieving herd immunity and improving safety when children return to school.
However, others have questioned whether childhood vaccination is worth the risk, as only 471 children under the age of 18 have died from COVID-19, accounting for 0.1 percent of all coronavirus deaths in the US.
Authorization could be given as early as the end of this week, and is expected early next week.
US regulators are expected to give Pfizer’s Covid vaccine to teens between the ages of 12 and 15 as early as the end of this week, officials told the New York Times.
If Pfizer’s shot gets the Food and Drug Administration (FDA) green light for younger teens, the Centers for Disease Control and Prevention (CDC) will most likely meet the next day and discuss the findings of Pfizer’s lawsuit.
The agency will then advise whether it believes the vaccine is safe and effective for ages 12 to 15.
Pfizer announced the results of its study of adolescents on March 31.
The company’s study of 2,260 volunteers found it prevented 100 percent of serious illnesses and deaths from COVID-19 among the teens.
In fact, the children showed a stronger immune response to the shot than the 16- to 25-year-old group that Pfizer had previously tested the vaccine in.
A press release on the result makes no mention of side effects in teens, but regulators will scour the data to make sure there are no red flags before giving the shot to teens.
For some parents who were nervous about their kids going back to school, the shot can’t come fast enough.
According to an analysis by the Washington Post, nearly half of American schools had returned to full in-person learning by March 23.
But the CDC has stated in no uncertain terms that neither teachers nor students need to be vaccinated to return to school safely.
Despite that recommendation, the Biden government has continued to urge states to prioritize teacher vaccination before authorizing vaccinations to be administered to the majority of school-age children.